Gothenburg, January 14, 2022 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immuno-oncological treatments focused on CAR T-cells and oncolytic viruses, publishes the annual report for 2021.
Elicera Therapeutics annual report is now available at the webpage https://www.elicera.com.
In the annual report CEO Jamal El-Mosleh comments; "I look forward to continuing Elicera's vital efforts in the fight against cancer through developing the next generation of cell and gene therapies, and through expanding awareness of our universally compatible CAR T-cell technology platform."
The Annual General Meeting will be held on March 7t at 3:00 p.m. at the offices of Advokatfirman Delphi (Mäster Samuelsgatan 17 in Stockholm).
For more information, contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)
Tel: +46 (0) 703 31 90 51
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical stage cell and gene therapy company developing the next generation of immuno-oncological treatments. The company has four drug candidates in development, two CAR T-cells and two oncolytic viruses, based on research carried out by Professor Magnus Essand's research group at Uppsala University. In addition, Elicera has a fully developed technology platform, iTANK, which can be used to optimize the effect of all CAR T-cell therapies under development and activate killer T-cells against cancer. The Elicera share (ELIC) is listed on the Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: firstname.lastname@example.org,tel: +468-503 000 50.
For more information, please visit www.elicera.se